Key Highlights
- Biogen, Beckman Coulter, and Fujirebio collaborate to develop tau-specific blood-based biomarkers for Alzheimer’s disease.
- Collaboration aims to advance diagnostic tools and therapies for tau pathology in AD.
- Potential to stratify patients and monitor treatment response in clinical trials and clinical practice.
Source: Business Wire
Notable Quotes
- “Collaborative efforts between Biogen, Beckman Coulter, and Fujirebio combine the strength of leading-edge biomarker development with innovative potential treatments focused on the tauopathy aspect of neurodegeneration, driving us closer to effective solutions.” — Kathleen Orland, Senior Vice President, General Manager, Chemistry, and Immunoassay at Beckman Coulter Diagnostics
- “Stratifying and monitoring patients for tau pathology is a growing need for the next generation of Alzheimer’s therapies, such as our pipeline of investigational tau-targeting therapies, including tau-directed ASO.” — Jane Grogan, Ph.D., Head of Research at Biogen
- “Blood-based biomarkers for tau pathology could advance the development and implementation of disease-modifying therapies for neurodegenerative disorders such as AD.” — Monte Wiltse, President & CEO at Fujirebio Diagnostics, Inc
SoHC's Take
The collaboration between Biogen, Beckman Coulter, and Fujirebio marks a significant step forward in the fight against Alzheimer’s disease. By focusing on the development of tau-specific blood-based biomarkers, this partnership not only aims to advance diagnostic tools but also paves the way for more precise and personalized treatment strategies. The integration of biomarker expertise with advanced diagnostic capabilities holds great promise for accelerating the development and clinical adoption of therapies targeting tau pathology, addressing a critical unmet need in Alzheimer’s disease management. This initiative underscores the importance of collaborative efforts in driving innovation and improving patient outcomes in neurodegenerative diseases.
